Why Nurix Therapeutics, Inc.’s (NRIX) Stock Is Up 5.14%
As of Tuesday, October 27, Nurix Therapeutics, Inc.’s NRIX share price has surged by 5.14%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. for co-development and co-commercialization of multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Commentary & Analysis
Why Nurix Therapeutics, Inc.’s (NRIX) Stock Is Up 5.96%
As of Thursday, October 15, Nurix Therapeutics, Inc.’s NRIX share price has surged by 5.96%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Nurix Therapeutics, Inc.’s (NRIX) Stock Is Up 5.74%
As of Wednesday, October 14, Nurix Therapeutics, Inc.’s NRIX share price has surged by 5.74%, which has investors questioning if this is right time to sell.Michael Rose
What You Need to Know About Nurix Therapeutics, Inc.'s Q4 Earnings
Nurix Therapeutics, Inc.'s fiscal Q4 earnings report was released on Monday, October 12. Let's dive in to see if (NRIX) missed or beat analyst's expectations.Jenna Brashear
Which Is a Better Investment, Alvotech or Nurix Therapeutics, Inc. Stock?
Learn more about whether Alvotech or Nurix Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Financial Summary
| Share Statistics | NRIX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,917.0 | $227.8 | 60% |
|
| Shares Out (Mil) | 116.2 | 53.4 | 65% |
|
| Institutional Ownership | 99.0% | 92.9% | 84% |
|
| Float (Mil) | 79.6 | 41.2 | 56% |
|
| Beta | 1.82 | 0.95 | 89% |
|
| Avg Daily Volume (000s) | 3,061 | 513 | 87% |
|
| Price Change (52-week) |
140.8% | 47.3% | 97% |
|
| Growth | NRIX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 36.4% | 12.8% | 92% |
|
| Net Income (5yr) | (43.7%) | (10.1%) | 8% |
|
| EPS (5yr) | (2.0%) | 15.8% | 28 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (21.8%) | (15.7%) | 30% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | $1.508 | $3.021 | ($1.276) | |
| Month Ago EPS | ($0.369) | $3.376 | ($1.065) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 3 | 1 | 0 | |
| Three Months Ago EPS | ($0.369) | $1.787 | ($1.439) | |
| Year/Year Chg | (68.1%) | (199.0%) | (85.2%) | |
| Financials | NRIX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $702 | $37 | 45% |
|
| Net Income (TTM) (Mil) | $295 | ($44) | 72% |
|
| EPS (TTM) | $2.757 | ($1.500) | 77% |
|
| Operating Cash Flow (TTM) (Mil) | $379 | ($34) | 68% |
|
| Net Cash Flow (TTM) (Mil) | $642 | $2 | 92% |
|
| Long-Term Debt (Q1) (Mil) | $62 | $4 | 41% |
|
| Enterprise Value (Q1) (Mil) | $1,603 | $177 | 46% |
|
| Valuation | NRIX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.01 | 2.22 | 68% |
|
| P/E | 9.9 | 20.4 | 17% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NRIX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 52.4% | 66.9% | 64% |
|
| Net Margin | 42.0% | (75.3%) | 95% |
|
| ROA | 34.3% | (47.1%) | 98% |
|
| ROE | 44.0% | (53.3%) | 92% |
|
| Liabilities to Assets | 19.0% | 29.3% | 12% |
|
| F-Score | 7 | 2 | 82% |
|
Passing Stock Screens
As of 10/27/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Price-to-Sales Screen
Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios.
| Performance Since Inception: | 13.0% |
| +/- S&P 500: | +5.5 |
